Biotech start-up Vaccitech files for US IPO Lakshmipriya Nair Apr 10, 2021 Vaccitech owns the technology behind the COVID-19 vaccine developed by Oxford University and AstraZeneca
Vaccitech begins Phase 1 clinical study of VTP-300 immunotherapeutic to treat chronic Hepatitis B EP News Bureau Jun 23, 2020 Once the VTP-300 prime dose is confirmed, Vaccitech plans to initiate a Phase 1b/2a study, HBV002, in Q3 2020
